Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00131
2007-06-01
Prospective
23 May 2007
Department of Ophthalmology and Visual Sciences The Chinese University of Hong Kong
Nil
Nil
Prof Dennis SC Lam
dennislam_cu_res@cuhk.edu.hk
Prof Dennis SC Lam
dennislam_cu_res@cuhk.edu.hk
The Safety and Efficacy of Combined Subtenon Triamcinolone Acetonide, Intravitreal Bevacizumab and Grid Laser Photocoagulation for Refractory Diabetic Macular Edema - A Pilot Study
Yes
2007-05-04
Refractory diabetic macular edema
Drug
Subtenon triamcinolone, intravitreal bevacizumab injections and macular photocoagulation
2 months
N/A
Inclusion criteria: 1. Aged 18 years or older 2. Recurrent or refractory clinically significant macular edema (CSME), after previous treatment(s), as defined according to the ETDRS 3. Macular edema of at least 250µm involving the fovea, as documented on optical coherent tomogram 4. Patients with best corrected visual acuity of better than 1.3 ETDRS logMAR units (equivalent to 20/400 on Snellen Chart) 5. Patients physically fit to receive treatment and comply with follow-up schedule 6. Informed consent Exclusion criteria 1. Ocular diseases other than cataract, diabetic retinopathy and refractive error. 2. Proliferative diabetic retinopathy 3. Media opacities which affect fundus examination or OCT measurements 4. Previous intraocular surgery except uncomplicated cataract extraction and posterior intraocular lens insertion more than 6 months prior to enrollment 5. Ocular laser procedure within 4 months 6. History of fluorescein allergy 7. Fellow eye visual acuity worse than 20/400
Non-randomized
Uncontrolled
Open label
Single group
2007-06-10
30
Not Yet Recruiting
1. Best-corrected visual acuity 2. Central foveal thickness as measured by optical coherent tomogram 3. Proportion of patients with a) moderate visual loss or b) stable/ gain in vision
1. Intraocular pressure 2. Changes in fluorescein angiography 3. Adverse events
2013-01-14
Yes
None
|
|
|
|
|
---|---|---|---|---|
No documents yet. |